Loading...
Loading...
PBLA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 5,877.0K |
| Gross Profit | -5,877.0K |
| Operating Expense | 5,877.0K |
| Operating I/L | -5,877.0K |
| Other Income/Expense | -82.0K |
| Interest Income | 49.0K |
| Pretax | -5,980.0K |
| Income Tax Expense | -147.0K |
| Net Income/Loss | -5,833.0K |
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing disruptive therapeutics for cancer treatment. The company's focus includes diseases of the pancreas such as pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other cancer indications. Its lead product candidate, SBP-101, is currently in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
